| Year |
Citation |
Score |
| 2024 |
Woodcock DJ, Sahli A, Teslo R, Bhandari V, Gruber AJ, Ziubroniewicz A, Gundem G, Xu Y, Butler A, Anokian E, Pope BJ, Jung CH, Tarabichi M, Dentro SC, Farmery JHR, ... ... Fraser M, et al. Genomic evolution shapes prostate cancer disease type. Cell Genomics. 100511. PMID 38428419 DOI: 10.1016/j.xgen.2024.100511 |
0.664 |
|
| 2022 |
Chen S, Petricca J, Ye W, Guan J, Zeng Y, Cheng N, Gong L, Shen SY, Hua JT, Crumbaker M, Fraser M, Liu S, Bratman SV, van der Kwast T, Pugh T, et al. The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors. Nature Communications. 13: 6467. PMID 36309516 DOI: 10.1038/s41467-022-34012-2 |
0.444 |
|
| 2022 |
Sjöström M, Zhao SG, Levy S, Zhang M, Ning Y, Shrestha R, Lundberg A, Herberts C, Foye A, Aggarwal R, Hua JT, Li H, Bergamaschi A, Maurice-Dror C, Maheshwari A, ... ... Fraser M, et al. The 5-Hydroxymethylcytosine Landscape of Prostate Cancer. Cancer Research. OF1-OF15. PMID 36251389 DOI: 10.1158/0008-5472.CAN-22-1123 |
0.531 |
|
| 2022 |
Burns D, Anokian E, Saunders EJ, Bristow RG, Fraser M, Reimand J, Schlomm T, Sauter G, Brors B, Korbel J, Weischenfeldt J, Waszak SM, Corcoran NM, Jung CH, Pope BJ, et al. Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study. European Urology. PMID 35659150 DOI: 10.1016/j.eururo.2022.05.007 |
0.664 |
|
| 2021 |
Livingstone J, Shiah YJ, Yamaguchi TN, Heisler LE, Huang V, Lesurf R, Gebo T, Carlin B, Eng S, Drysdale E, Green J, van der Kwast T, Bristow RG, Fraser M, Boutros PC. The telomere length landscape of prostate cancer. Nature Communications. 12: 6893. PMID 34824250 DOI: 10.1038/s41467-021-27223-6 |
0.621 |
|
| 2021 |
Plante A, Dallaire F, Grosset AA, Nguyen T, Birlea M, Wong J, Daoust F, Roy N, Kougioumoutzakis A, Azzi F, Aubertin K, Kadoury S, Latour M, Albadine R, Prendeville S, ... ... Fraser M, et al. Dimensional reduction based on peak fitting of Raman micro spectroscopy data improves detection of prostate cancer in tissue specimens. Journal of Biomedical Optics. 26. PMID 34743445 DOI: 10.1117/1.JBO.26.11.116501 |
0.477 |
|
| 2021 |
Fraser M, Livingstone J, Wrana JL, Finelli A, He HH, van der Kwast T, Zlotta AR, Bristow RG, Boutros PC. Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse. Nature Communications. 12: 6248. PMID 34716314 DOI: 10.1038/s41467-021-26489-0 |
0.65 |
|
| 2021 |
Hawley JR, Zhou S, Arlidge C, Grillo G, Kron KJ, Hugh-White R, van der Kwast TH, Fraser M, Boutros PC, Bristow RG, Lupien M. Reorganization of the 3D genome pinpoints non-coding drivers of primary prostate tumors. Cancer Research. PMID 34642184 DOI: 10.1158/0008-5472.CAN-21-2056 |
0.6 |
|
| 2021 |
Ahmed M, Soares F, Xia JH, Yang Y, Li J, Guo H, Su P, Tian Y, Lee HJ, Wang M, Akhtar N, Houlahan KE, Bosch A, Zhou S, Mazrooei P, ... ... Fraser M, et al. CRISPRi screens reveal a DNA methylation-mediated 3D genome dependent causal mechanism in prostate cancer. Nature Communications. 12: 1781. PMID 33741908 DOI: 10.1038/s41467-021-21867-0 |
0.379 |
|
| 2021 |
Chen S, Zhu G, Yang Y, Wang F, Xiao YT, Zhang N, Bian X, Zhu Y, Yu Y, Liu F, Dong K, Mariscal J, Liu Y, Soares F, Loo Yau H, ... ... Fraser M, et al. Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression. Nature Cell Biology. 23: 87-98. PMID 33420488 DOI: 10.1038/s41556-020-00613-6 |
0.462 |
|
| 2021 |
Fraser M. Evidence for Focal Grade Group Progression in Low-risk Prostate Cancer. European Urology. 79: 466-467. PMID 33357993 DOI: 10.1016/j.eururo.2020.11.022 |
0.463 |
|
| 2021 |
Fraser M. Evidence for Focal Grade Group Progression in Low-risk Prostate Cancer European Urology. 79: 466-467. DOI: 10.1016/j.eururo.2020.11.022 |
0.463 |
|
| 2020 |
Grosset AA, Dallaire F, Nguyen T, Birlea M, Wong J, Daoust F, Roy N, Kougioumoutzakis A, Azzi F, Aubertin K, Kadoury S, Latour M, Albadine R, Prendeville S, Boutros P, ... Fraser M, et al. Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy case-control study with multicohort validation. Plos Medicine. 17: e1003281. PMID 32797086 DOI: 10.1371/Journal.Pmed.1003281 |
0.616 |
|
| 2020 |
Brastianos HC, Murgic J, Salcedo A, Chua MLK, Meng A, Fraser M, Brundage M, Fleshner NE, van der Kwast T, Bristow RG, Boutros PC, Berlin A. Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate Cancer. European Urology Oncology. PMID 32605887 DOI: 10.1016/J.Euo.2020.06.005 |
0.64 |
|
| 2020 |
Zhou S, Hawley JR, Soares F, Grillo G, Teng M, Madani Tonekaboni SA, Hua JT, Kron KJ, Mazrooei P, Ahmed M, Arlidge C, Yun HY, Livingstone J, Huang V, Yamaguchi TN, ... ... Fraser M, et al. Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer. Nature Communications. 11: 441. PMID 31974375 DOI: 10.1038/S41467-020-14318-9 |
0.657 |
|
| 2020 |
Li Y, Yang R, Henzler CM, Ho Y, Passow C, Auch B, Carreira S, Nava Rodrigues D, Bertan C, Hwang TH, Quigley DA, Dang HX, Morrissey C, Fraser M, Plymate SR, et al. Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31932493 DOI: 10.1158/1078-0432.Ccr-19-3023 |
0.574 |
|
| 2019 |
Fraser M, Rouette A. Prostate Cancer Genomic Subtypes. Advances in Experimental Medicine and Biology. 1210: 87-110. PMID 31900906 DOI: 10.1007/978-3-030-32656-2_5 |
0.581 |
|
| 2019 |
Mazrooei P, Kron KJ, Zhu Y, Zhou S, Grillo G, Mehdi T, Ahmed M, Severson TM, Guilhamon P, Armstrong NS, Huang V, Yamaguchi TN, Fraser M, van der Kwast T, Boutros PC, et al. Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors. Cancer Cell. PMID 31735626 DOI: 10.1016/J.Ccell.2019.10.005 |
0.611 |
|
| 2019 |
Houlahan KE, Shiah YJ, Gusev A, Yuan J, Ahmed M, Shetty A, Ramanand SG, Yao CQ, Bell C, O'Connor E, Huang V, Fraser M, Heisler LE, Livingstone J, Yamaguchi TN, et al. Genome-wide germline correlates of the epigenetic landscape of prostate cancer. Nature Medicine. PMID 31591588 DOI: 10.1038/S41591-019-0579-Z |
0.602 |
|
| 2019 |
Jeon J, Olkhov-Mitsel E, Xie H, Yao CQ, Zhao F, Jahangiri S, Cuizon C, Scarcello S, Jeyapala R, Watson JD, Fraser M, Ray J, Commisso K, Loblaw A, Fleshner NE, et al. Temporal stability and prognostic biomarker potential of the prostate cancer urine transcriptome. Journal of the National Cancer Institute. PMID 31161221 DOI: 10.1093/Jnci/Djz112 |
0.611 |
|
| 2019 |
Fraser M. Separating the Dreadful from the Merely Bad: Towards Prognostic and Predictive Biomarkers in Metastatic Castration-resistant Prostate Cancer. European Urology. 76: 572-573. PMID 31010599 DOI: 10.1016/J.Eururo.2019.04.005 |
0.534 |
|
| 2019 |
Sinha A, Huang V, Livingstone J, Wang J, Fox NS, Kurganovs N, Ignatchenko V, Fritsch K, Donmez N, Heisler LE, Shiah YJ, Yao CQ, Alfaro JA, Volik S, Lapuk A, ... Fraser M, et al. The Proteogenomic Landscape of Curable Prostate Cancer. Cancer Cell. 35: 414-427.e6. PMID 30889379 DOI: 10.1016/J.Ccell.2019.02.005 |
0.715 |
|
| 2019 |
Taylor RA, Fraser M, Rebello RJ, Boutros PC, Murphy DG, Bristow RG, Risbridger GP. The influence of BRCA2 mutation on localized prostate cancer. Nature Reviews. Urology. PMID 30808988 DOI: 10.1038/S41585-019-0164-8 |
0.653 |
|
| 2019 |
Chen S, Huang V, Xu X, Livingstone J, Soares F, Jeon J, Zeng Y, Hua JT, Petricca J, Guo H, Wang M, Yousif F, Zhang Y, Donmez N, Ahmed M, ... ... Fraser M, et al. Widespread and Functional RNA Circularization in Localized Prostate Cancer. Cell. 176: 831-843.e22. PMID 30735634 DOI: 10.1016/J.Cell.2019.01.025 |
0.586 |
|
| 2019 |
Bhandari V, Hoey C, Liu LY, Lalonde E, Ray J, Livingstone J, Lesurf R, Shiah YJ, Vujcic T, Huang X, Espiritu SMG, Heisler LE, Yousif F, Huang V, Yamaguchi TN, ... ... Fraser M, et al. Molecular landmarks of tumor hypoxia across cancer types. Nature Genetics. PMID 30643250 DOI: 10.1038/S41588-018-0318-2 |
0.549 |
|
| 2019 |
Fraser M, Koontz B, Emmenegger U, De Meerleer G, Khoo V, Feng F, Corcoran NM, Hovens CM, Tran PT, Ost P, Boutros PC. What Is Oligometastatic Prostate Cancer? European Urology Focus. PMID 30642810 DOI: 10.1016/J.Euf.2018.12.009 |
0.553 |
|
| 2019 |
Vinayak B, Liu L, Espirritu S, Lalonde E, Yamaguchi T, Heisler L, Livingstone J, Huang V, Shiah Y, Sabelnykova V, Yousif F, Fraser M, Chua M, Van Der Kwast T, Liu SK, et al. The molecular hallmarks and clinical consequences of tumor hypoxia in prostate cancer. Journal of Clinical Oncology. 37: 81-81. DOI: 10.1200/Jco.2019.37.7_Suppl.81 |
0.712 |
|
| 2019 |
Brastianos H, Murgic J, Salcedo A, Chua MLK, Meng A, Fraser M, Brundage MD, Fleshner NE, van der Kwast T, Bristow RG, Boutros PC, Berlin A. The impact of intratumoral heterogeneity on prognostic biomarkers in localized prostate cancer. Journal of Clinical Oncology. 37: 46-46. DOI: 10.1200/Jco.2019.37.7_Suppl.46 |
0.634 |
|
| 2019 |
Trudel D, Grosset A, Dallaire F, Nguyen T, Kougioumoutzakis A, Azzi F, Aubertin K, Saad F, Latour M, Albadine R, Boutros P, Fraser M, Bristow RG, Kwast Tvd, Benzerdjeb N, et al. Raman microscopy for the identification of an aggressive variant of prostate cancer, intraductal carcinoma of the prostate Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz239.002 |
0.578 |
|
| 2019 |
Brastianos H, Murgic J, Salcedo A, Chua M, Meng A, Fraser M, Brundage M, Fleshner N, van der Kwast T, Bristow R. 39 Determination of the Impact of Intratumoural Heterogeneity on Prognostic Biomarkers in Localized Prostate Cancer Radiotherapy and Oncology. 139: S19-S20. DOI: 10.1016/S0167-8140(19)33325-0 |
0.563 |
|
| 2018 |
Cooper CI, Yao D, Sendorek DH, Yamaguchi TN, P'ng C, Houlahan KE, Caloian C, Fraser M, Ellrott K, Margolin AA, Bristow RG, Stuart JM, Boutros PC. Valection: design optimization for validation and verification studies. Bmc Bioinformatics. 19: 339. PMID 30253747 DOI: 10.1186/S12859-018-2391-Z |
0.429 |
|
| 2018 |
Berlin A, Murgic J, Hosni A, Pintilie M, Salcedo A, Fraser M, Kamel-Reid S, Zhang J, Wang Q, Ch'ng C, Deheshi S, Davicioni E, van der Kwast T, Boutros PC, Bristow RG, et al. Genomic classifier for guiding treatment of intermediate-risk prostate cancers to dose-escalated image-guided radiotherapy without hormone therapy. International Journal of Radiation Oncology, Biology, Physics. PMID 30170099 DOI: 10.1016/J.Ijrobp.2018.08.030 |
0.679 |
|
| 2018 |
Espiritu SMG, Liu LY, Rubanova Y, Bhandari V, Holgersen EM, Szyca LM, Fox NS, Chua MLK, Yamaguchi TN, Heisler LE, Livingstone J, Wintersinger J, Yousif F, Lalonde E, Rouette A, ... ... Fraser M, et al. The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression. Cell. PMID 29681457 DOI: 10.1016/J.Cell.2018.03.029 |
0.636 |
|
| 2018 |
Wedge DC, Gundem G, Mitchell T, Woodcock DJ, Martincorena I, Ghori M, Zamora J, Butler A, Whitaker H, Kote-Jarai Z, Alexandrov LB, Van Loo P, Massie CE, Dentro S, Warren AY, ... ... Fraser M, et al. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nature Genetics. PMID 29662167 DOI: 10.1038/S41588-018-0086-Z |
0.654 |
|
| 2018 |
Böttcher R, Kweldam CF, Livingstone J, Lalonde E, Yamaguchi TN, Huang V, Yousif F, Fraser M, Bristow RG, van der Kwast T, Boutros PC, Jenster G, van Leenders GJLH. Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations. Bmc Cancer. 18: 8. PMID 29295717 DOI: 10.1186/S12885-017-3976-Z |
0.652 |
|
| 2018 |
Chua M, Murgic J, Hosni A, Salcedo A, Kamel-Reid S, Berlin A, Pintile M, Fraser M, Van Der Kwast T, Boutros PC, Bristow RG. A biopsy-based genomic classifier to predict biochemical failure after definitive radiation without hormone therapy in a prospective cohort of intermediate risk prostate cancer. Journal of Clinical Oncology. 36: 68-68. DOI: 10.1200/Jco.2018.36.6_Suppl.68 |
0.657 |
|
| 2018 |
Porter LH, Lawrence MG, Pezaro C, Thorne H, Ilic D, Papargiris M, Fraser M, Livingstone J, Murphy DG, Frydenberg M, Bolton D, Moon D, Clouston D, Kwast Tvd, Boutros PC, et al. Abstract B100: High-risk pathologic and genomic features of BRCA2-mutant prostate cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Prca2017-B100 |
0.677 |
|
| 2018 |
Fraser ME, Kwast Tvd, Bristow RG. Abstract NG06: The clinico-genomics of localized, non-indolent prostate cancer: the CPC-GENE experience Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ng06 |
0.696 |
|
| 2018 |
Chua M, Bristow R, Murgic J, Hosni Abdalaty A, Salcedo A, Kamel-Reid S, Fraser M, Zhang J, Wang Q, Ch'ng C, Deheshi S, Davicioni E, Van der Kwast T, Boutros P, Berlin A. A Biopsy Based Genomic Classifier Predicts Biochemical Failure and Metastasis after Definitive Radiation without Hormone Therapy in a Prospective Cohort of Intermediate-Risk Prostate Cancer International Journal of Radiation Oncology*Biology*Physics. 102: S99. DOI: 10.1016/J.Ijrobp.2018.06.254 |
0.61 |
|
| 2017 |
Fraser M, Boutros PC, Bristow RG. A Partner in Crime: Tumor-associated Stroma and Metastatic Prostate Cancer. European Urology. PMID 29275835 DOI: 10.1016/J.Eururo.2017.11.029 |
0.674 |
|
| 2017 |
Hopkins JF, Sabelnykova VY, Weischenfeldt J, Simon R, Aguiar JA, Alkallas R, Heisler LE, Zhang J, Watson JD, Chua MLK, Fraser M, Favero F, Lawerenz C, Plass C, Sauter G, et al. Mitochondrial mutations drive prostate cancer aggression. Nature Communications. 8: 656. PMID 28939825 DOI: 10.1038/S41467-017-00377-Y |
0.574 |
|
| 2017 |
Kron KJ, Murison A, Zhou S, Huang V, Yamaguchi TN, Shiah YJ, Fraser M, van der Kwast T, Boutros PC, Bristow RG, Lupien M. TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer. Nature Genetics. PMID 28783165 DOI: 10.1038/Ng.3930 |
0.613 |
|
| 2017 |
Shiah YJ, Fraser M, Bristow RG, Boutros PC. Comparison of Pre-processing Methods for Infinium HumanMethylation450 BeadChip Array. Bioinformatics (Oxford, England). PMID 28605401 DOI: 10.1093/Bioinformatics/Btx372 |
0.399 |
|
| 2017 |
Chua MLK, Lo W, Pintilie M, Murgic J, Lalonde E, Bhandari V, Mahamud O, Gopalan A, Kweldam CF, van Leenders GJLH, Verhoef EI, Hoogland AM, Livingstone J, Berlin A, Dal Pra A, ... ... Fraser M, et al. A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. European Urology. PMID 28511883 DOI: 10.1016/J.Eururo.2017.04.034 |
0.693 |
|
| 2017 |
Briollais L, Ozcelik H, Xu J, Kwiatkowski M, Lalonde E, Sendorek DH, Fleshner NE, Recker F, Kuk C, Olkhov-Mitsel E, Juvet T, Prassas I, Trachtenberg J, Toi A, Fraser M, et al. Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer. Journal of the National Cancer Institute. 109. PMID 28376164 DOI: 10.1093/Jnci/Djw258 |
0.694 |
|
| 2017 |
Fraser M, Sabelnykova VY, Yamaguchi TN, Heisler LE, Livingstone J, Huang V, Shiah YJ, Yousif F, Lin X, Masella AP, Fox NS, Xie M, Prokopec SD, Berlin A, Lalonde E, et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature. PMID 28068672 DOI: 10.1038/Nature20788 |
0.635 |
|
| 2017 |
Taylor RA, Fraser M, Livingstone J, Espiritu SM, Thorne H, Huang V, Lo W, Shiah YJ, Yamaguchi TN, Sliwinski A, Horsburgh S, Meng A, Heisler LE, Yu N, Yousif F, et al. Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. Nature Communications. 8: 13671. PMID 28067867 DOI: 10.1038/Ncomms13671 |
0.629 |
|
| 2017 |
Fox NS, Lalonde E, Livingstone J, Hopkins J, Shiah Y, Huang V, Yamaguchi T, Sabelnykova V, Heisler L, Fraser M, van der Kwast T, Bristow RG, Boutros PC. Integrated somatic subtypes of localized intermediate-risk prostate cancer. Journal of Clinical Oncology. 35: e560-e560. DOI: 10.1200/Jco.2017.35.6_Suppl.E560 |
0.65 |
|
| 2017 |
Chua M, Holgersen E, Sabelnykova V, Salcedo A, Meng A, Fraser M, Van Der Kwast T, Boutros PC, Bristow RG. Genomic architecture of radioresistant prostate cancer. Journal of Clinical Oncology. 35: 26-26. DOI: 10.1200/Jco.2017.35.6_Suppl.26 |
0.676 |
|
| 2017 |
Chua MLK, Holgersen E, Sabelnykova V, Salcedo A, Meng A, Fraser M, Kwast Tvd, Boutros PC, Bristow RG. Abstract 5860: Genomic architecture of prostate cancer at recurrence following radiotherapy Cancer Research. 77: 5860-5860. DOI: 10.1158/1538-7445.Am2017-5860 |
0.693 |
|
| 2017 |
Briollais L, Ozcelik H, Xu J, Kwiatkowski M, Lalonde E, Sendorek DH, Fleshner NE, Recker F, Kuk C, Olkhov-Mitsel E, Savas S, Hanna S, Juvet T, Hunter GA, Friedlander M, ... ... Fraser M, et al. PD65-01 GERMLINE MUTATIONS IN THE KALLIKREIN 6 REGION AND PREDISPOSITION FOR AGGRESSIVE PROSTATE CANCER Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.2951 |
0.572 |
|
| 2016 |
Lalonde E, Alkallas R, Chua ML, Fraser M, Haider S, Meng A, Zheng J, Yao CQ, Picard V, Orain M, Hovington H, Murgic J, Berlin A, Lacombe L, Bergeron A, et al. Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. European Urology. PMID 27815082 DOI: 10.1016/J.Eururo.2016.10.013 |
0.672 |
|
| 2016 |
Chua ML, Salcedo A, Meng A, Zhang J, Fleshner N, Fraser M, van der Kwast T, Boutros PC, Bristow RG. Genomic Architecture of Prostate Cancer at Recurrence Following Radiation Therapy. International Journal of Radiation Oncology, Biology, Physics. 96: S114. PMID 27675559 DOI: 10.1016/J.Ijrobp.2016.06.280 |
0.617 |
|
| 2016 |
So J, Chua ML, Lalonde E, Pra AD, Berlin A, Orain M, Hovington H, Bergeron A, Fradet Y, Têtu B, Meng A, Zhang J, Zafarana G, Livingstone J, Pintilie M, ... ... Fraser M, et al. Prognostic Significance of Tonsil Expression and the Homologous Recombination Pathway in Intermediate-Risk Prostate Cancer Recurrence. International Journal of Radiation Oncology, Biology, Physics. 96: S113. PMID 27675557 DOI: 10.1016/j.ijrobp.2016.06.278 |
0.64 |
|
| 2016 |
Guo H, Ahmed M, Zhang F, Yao CQ, Li S, Liang Y, Hua J, Soares F, Sun Y, Langstein J, Li Y, Poon C, Bailey SD, Desai K, Fei T, ... ... Fraser M, et al. Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. Nature Genetics. PMID 27526323 DOI: 10.1038/Ng.3637 |
0.689 |
|
| 2016 |
Masella AP, Lalansingh CM, Sivasundaram P, Fraser M, Bristow RG, Boutros PC. BAMQL: a query language for extracting reads from BAM files. Bmc Bioinformatics. 17: 305. PMID 27516195 DOI: 10.1186/S12859-016-1162-Y |
0.346 |
|
| 2016 |
Boutros PC, Fraser M, van der Kwast T, Bristow RG. Clonality of localized and metastatic prostate cancer. Current Opinion in Urology. 26: 219-24. PMID 26885716 DOI: 10.1097/Mou.0000000000000279 |
0.687 |
|
| 2016 |
Chua M, Lalonde E, Mahamud O, Berlin A, Pra AD, Orain M, Picard V, Hovington H, Bergeron A, Fradet Y, Têtu B, Meng A, Zhang J, Zafarana G, Livingstone J, ... ... Fraser M, et al. Copy number alterations of DNA mismatch repair (MMR) genes as novel prognostic markers in localised prostate cancer (CaP). Journal of Clinical Oncology. 34: 96-96. DOI: 10.1200/Jco.2016.34.2_Suppl.96 |
0.584 |
|
| 2016 |
So J, Chua M, Lalonde E, Mahamud O, Berlin A, Dal Pra A, Orain M, Hovington H, Bergeron A, Fradet Y, Têtu B, Meng A, Zhang J, Zafarana G, Livingstone J, ... ... Fraser M, et al. Prognostic value of copy-number alterations of the Cohesin complex in intermediate-risk prostate cancer recurrence. Journal of Clinical Oncology. 34: 49-49. DOI: 10.1200/Jco.2016.34.2_Suppl.49 |
0.668 |
|
| 2016 |
Mahamud O, Chua M, Lalonde E, So J, Dal Pra A, Berlin A, Orain M, Picard V, Hovington H, Bergeron A, Fradet Y, Têtu B, Zafarana G, Meng A, Livingstone J, ... ... Fraser M, et al. Copy number alterations of P53, RB1, and MDM2 as prognostic markers in intermediate-risk prostate cancer. Journal of Clinical Oncology. 34: 117-117. DOI: 10.1200/Jco.2016.34.2_Suppl.117 |
0.586 |
|
| 2016 |
Chua M, Murgic J, Pintilie M, Lalonde E, Berlin A, Livingstone J, Dal Pra A, Meng A, Zhang J, Fradet Y, Têtu B, Fleshner NE, Fraser M, Boutros P, van der Kwast T, et al. Combinatorial genomic and pathological indices for integrated stratification of unfavorable intermediate-risk prostate cancer. Journal of Clinical Oncology. 34: 5051-5051. DOI: 10.1200/Jco.2016.34.15_Suppl.5051 |
0.661 |
|
| 2016 |
Hopkins JF, Sabelnykova VY, Watson J, Heisler LE, Zhang J, Fraser M, Kwast Tvd, Bristow RG, Boutros PC. Abstract 98: The somatic mutational landscape of the mitochondrial genome in prostate cancer: evaluation of clinical impact Cancer Research. 76: 98-98. DOI: 10.1158/1538-7445.Am2016-98 |
0.621 |
|
| 2016 |
Chua MLK, Murgic J, Pintilie M, Lalonde E, Kweldam C, Lo W, Berlin A, Pra AD, Orain M, Picard V, Hovington H, Begeron A, Fradet Y, Tetu B, Livingstone J, ... ... Fraser M, et al. Abstract 4339: Prognostic significance of copy number alteration burden in unfavorable intermediate-risk prostate cancers harboring intraductal carcinoma and cribriform architecture Cancer Research. 76: 4339-4339. DOI: 10.1158/1538-7445.Am2016-4339 |
0.611 |
|
| 2016 |
Fraser ME, Kwast Tvd, McPherson J, Collins CC, Fradet Y, Tetu B, Bergeron A, Bristow RG, Boutros PC. Abstract 118: A comprehensive profile of the genomic architecture of curable prostate cancer Cancer Research. 76: 118-118. DOI: 10.1158/1538-7445.Am2016-118 |
0.668 |
|
| 2016 |
So J, Chua M, Lalonde E, Mahamud O, Berlin A, Pra AD, Orain M, Hovington H, Bergeron A, Fradet Y, Têtu B, Meng A, Zhang J, Zafarana G, Pintilie M, ... ... Fraser M, et al. 227: Prognostic Significance of Tonsl Expression and the Homologous Recombination Pathway in Intermediate-Risk Prostate Cancer Recurrence Radiotherapy and Oncology. 120: S82-S83. DOI: 10.1016/S0167-8140(16)33626-X |
0.678 |
|
| 2015 |
Cooper CS, Eeles R, Wedge DC, Van Loo P, Gundem G, Alexandrov LB, Kremeyer B, Butler A, Lynch AG, Camacho N, Massie CE, Kay J, Luxton HJ, Edwards S, Kote-Jarai Z, ... ... Fraser M, et al. Corrigendum: Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nature Genetics. 47: 689. PMID 26018901 DOI: 10.1038/Ng0615-689B |
0.669 |
|
| 2015 |
Boutros PC, Fraser M, Harding NJ, de Borja R, Trudel D, Lalonde E, Meng A, Hennings-Yeomans PH, McPherson A, Sabelnykova VY, Zia A, Fox NS, Livingstone J, Shiah YJ, Wang J, et al. Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nature Genetics. 47: 736-45. PMID 26005866 DOI: 10.1038/Ng.3315 |
0.645 |
|
| 2015 |
Cooper CS, Eeles R, Wedge DC, Van Loo P, Gundem G, Alexandrov LB, Kremeyer B, Butler A, Lynch AG, Camacho N, Massie CE, Kay J, Luxton HJ, Edwards S, Kote-Jarai Z, ... ... Fraser M, et al. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nature Genetics. 47: 367-72. PMID 25730763 DOI: 10.1038/Ng.3221 |
0.676 |
|
| 2015 |
Fraser M, Berlin A, Bristow RG, van der Kwast T. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. Urologic Oncology. 33: 85-94. PMID 24768356 DOI: 10.1016/J.Urolonc.2013.10.020 |
0.667 |
|
| 2015 |
Fraser ME, Sabelnykova VY, Yamaguchi TN, Meng A, Heisler LE, Zhang J, Livingstone J, Huang V, Masella AP, Yousif F, Xie M, Harding NJ, Lin X, Kong H, Prokopec SD, et al. Abstract 2966: The mutational landscape of localized gleason 6 and 7 prostate cancer Cancer Research. 75: 2966-2966. DOI: 10.1158/1538-7445.Am2015-2966 |
0.672 |
|
| 2014 |
Zhukova N, Ramaswamy V, Remke M, Martin DC, Castelo-Branco P, Zhang CH, Fraser M, Tse K, Poon R, Shih DJ, Baskin B, Ray PN, Bouffet E, Dirks P, von Bueren AO, et al. WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Acta Neuropathologica Communications. 2: 174. PMID 25539912 DOI: 10.1186/S40478-014-0174-Y |
0.505 |
|
| 2014 |
Lalonde E, Ishkanian AS, Sykes J, Fraser M, Ross-Adams H, Erho N, Dunning MJ, Halim S, Lamb AD, Moon NC, Zafarana G, Warren AY, Meng X, Thoms J, Grzadkowski MR, et al. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. The Lancet. Oncology. 15: 1521-32. PMID 25456371 DOI: 10.1016/S1470-2045(14)71021-6 |
0.706 |
|
| 2014 |
Chong LC, Albuquerque MA, Harding NJ, Caloian C, Chan-Seng-Yue M, de Borja R, Fraser M, Denroche RE, Beck TA, van der Kwast T, Bristow RG, McPherson JD, Boutros PC. SeqControl: process control for DNA sequencing. Nature Methods. 11: 1071-5. PMID 25173705 DOI: 10.1038/Nmeth.3094 |
0.514 |
|
| 2014 |
Govind SK, Zia A, Hennings-Yeomans PH, Watson JD, Fraser M, Anghel C, Wyatt AW, van der Kwast T, Collins CC, McPherson JD, Bristow RG, Boutros PC. ShatterProof: operational detection and quantification of chromothripsis. Bmc Bioinformatics. 15: 78. PMID 24646301 DOI: 10.1186/1471-2105-15-78 |
0.546 |
|
| 2014 |
Miller JK, Buchner N, Timms L, Tam S, Luo X, Brown AM, Pasternack D, Bristow RG, Fraser M, Boutros PC, McPherson JD. Use of Sequenom sample ID Plus® SNP genotyping in identification of FFPE tumor samples. Plos One. 9: e88163. PMID 24551080 DOI: 10.1371/Journal.Pone.0088163 |
0.464 |
|
| 2014 |
Bristow R, Lalonde E, Milosevic M, Sykes J, Van der Kwast T, Fraser M, Fotouhi-Ghiam A, Boutros P. OC-0139: Complementarity of genomic instability & hypoxia indices for predicting prostate cancer recurrence Radiotherapy and Oncology. 111: S54. DOI: 10.1016/S0167-8140(15)30244-9 |
0.5 |
|
| 2013 |
Fraser ME, Borja Rd, Trudel D, Harding NJ, Hennings-Yeomans PH, Meng A, Lalonde ER, Brown A, Fox NS, Chong T, Zia A, Sam M, Wang J, Chan-Seng-Yue MA, Johns J, et al. Abstract 2003: A molecular portrait of potentially curable prostate cancer. Cancer Research. 73: 2003-2003. DOI: 10.1158/1538-7445.Am2013-2003 |
0.613 |
|
| 2013 |
Lalonde E, Boutros PC, Fraser M, Borja Rd, Harding NJ, Trudel D, Meng A, Hennings-Yeomans PH, McPherson A, Zia A, Wang J, Beck T, Fox NS, Chong T, Sam M, et al. Abstract B129: Clinical implications of inter- and intra- prostatic heterogeneity. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B129 |
0.706 |
|
| 2013 |
Fraser M, Berlin A, Ouellet V, Saad F, Bristow RG. Prostate Cancer Genomics as a Driver of Personalized Medicine Cancer Genomics: From Bench to Personalized Medicine. 233-245. DOI: 10.1016/B978-0-12-396967-5.00014-1 |
0.661 |
|
| 2012 |
Fraser M, Zhao H, Luoto KR, Lundin C, Coackley C, Chan N, Joshua AM, Bismar TA, Evans A, Helleday T, Bristow RG. PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1015-27. PMID 22114138 DOI: 10.1158/1078-0432.Ccr-11-2189 |
0.693 |
|
| 2012 |
Zhukova N, Martin D, Lipman T, Castelo-Branco P, Zhang CH, Fraser M, Baskin B, Ray P, Bouffet E, Bristow R, Alman BA, Taylor MD, Malkin D, Hawkins C, Tabori U. Abstract LB-210: Abrogation of mutant TP53 radiation resistance by lithium induced CTNNB1 (β-catenin) activation in medulloblastoma. Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-210 |
0.519 |
|
| 2012 |
Sam MR, Chong T, Zia A, Lalonde E, Yousif F, Denroche R, Chan-Seng-Yue M, Meng A, Fraser M, Johns J, Timms L, Borja Rd, Starmans MHW, Wang J, Hennings-Yeomans P, et al. Abstract 3184: Whole genome sequencing of low-input fresh frozen prostate cancer biopsies Cancer Research. 72: 3184-3184. DOI: 10.1158/1538-7445.Am2012-3184 |
0.67 |
|
| 2011 |
Fraser M, Harding SM, Zhao H, Coackley C, Durocher D, Bristow RG. MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks. Cell Cycle (Georgetown, Tex.). 10: 2218-32. PMID 21623170 DOI: 10.4161/Cc.10.13.16305 |
0.662 |
|
| 2011 |
Al-Bahlani S, Fraser M, Wong AY, Sayan BS, Bergeron R, Melino G, Tsang BK. P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanism. Oncogene. 30: 4219-30. PMID 21516125 DOI: 10.1038/Onc.2011.134 |
0.532 |
|
| 2010 |
Fraser ME, Zhao H, Lundin C, Evans A, Helleday T, Bristow RG. Abstract 3932: Loss of PTEN sensitizes cells to DNA damaging agents in a RAD51-independent manner Cancer Research. 70: 3932-3932. DOI: 10.1158/1538-7445.Am10-3932 |
0.584 |
|
| 2009 |
Bristow RG, Zhao H, Fraser M. Abstract A122: The tyrosine kinase inhibitor MP470 inhibits RAD51‐mediated homologous recombination and increases tumor cell radio‐ and chemosensitivity Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A122 |
0.54 |
|
| 2008 |
Leung EL, Fraser M, Fiscus RR, Tsang BK. Cisplatin alters nitric oxide synthase levels in human ovarian cancer cells: Involvement in p53 regulation and cisplatin resistance British Journal of Cancer. 98: 1803-1809. PMID 18506185 DOI: 10.1038/Sj.Bjc.6604375 |
0.553 |
|
| 2008 |
Yang X, Fraser M, Abedini MR, Bai T, Tsang BK. Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by Akt. British Journal of Cancer. 98: 803-8. PMID 18283299 DOI: 10.1038/Sj.Bjc.6604223 |
0.537 |
|
| 2008 |
Fraser M, Bai T, Tsang BK. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. International Journal of Cancer. 122: 534-46. PMID 17918180 DOI: 10.1002/Ijc.23086 |
0.569 |
|
| 2006 |
Yan X, Fraser M, Qiu Q, Tsang BK. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner. Gynecologic Oncology. 102: 348-55. PMID 16545436 DOI: 10.1016/J.Ygyno.2005.12.033 |
0.597 |
|
| 2006 |
Yang X, Fraser M, Moll UM, Basak A, Tsang BK. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Research. 66: 3126-36. PMID 16540663 DOI: 10.1158/0008-5472.Can-05-0425 |
0.535 |
|
| 2006 |
Fraser M, Chan SL, Chan SS, Fiscus RR, Tsang BK. Regulation of p53 and suppression of apoptosis by the soluble guanylyl cyclase/cGMP pathway in human ovarian cancer cells. Oncogene. 25: 2203-12. PMID 16288207 DOI: 10.1038/Sj.Onc.1209251 |
0.552 |
|
| 2003 |
Fraser M, Leung BM, Yan X, Dan HC, Cheng JQ, Tsang BK. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Research. 63: 7081-8. PMID 14612499 |
0.525 |
|
| 2003 |
Fraser M, Leung B, Jahani-Asl A, Yan X, Thompson WE, Tsang BK. Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reproductive Biology and Endocrinology : Rb&E. 1: 66. PMID 14609433 DOI: 10.1186/1477-7827-1-66 |
0.588 |
|
| 2002 |
Cheng JQ, Jiang X, Fraser M, Li M, Dan HC, Sun M, Tsang BK. Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 5: 131-46. PMID 12237081 DOI: 10.1016/S1368-7646(02)00003-1 |
0.587 |
|
| Show low-probability matches. |